EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam

Dariusz A Hareza, Sara E Cosgrove, Robert A Bonomo iD, Kathryn Dzintars, Sara M Karaba iD, Armani M Hawes, Tsigereda Tekle, Patricia J Simner iD, Pranita D Tamma iD

Antimicrobial Agents and Chemotherapy · 08.10.2024 · 68 (10)

DOI: 10.1128/aac.00907-24 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 08.10.2024. Verfasst von Dariusz A Hareza und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Ceftazidime, Cephalosporins, Drug Combinations, Azabicyclo Compounds. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HHS | National Institutes of Health (NIH), NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Few studies compare outcomes of patients with difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam. A multicenter prospective study was conducted of unique patients with DTR P. aeruginosa infections from 2018 to 2023 receiving >72 h of ceftolozane-tazobactam or ceftazidime-avibactam, with confirmation that the P. aeruginosa isolate was susceptible to the agent administered by broth microdilution. Inverse probability weighting (IPW) incorporating propensity scores was utilized to ensure balanced baseline characteristics. Regression performed on the post-IPW group determined 30-day mortality and subsequent emergence of resistance (i.e., ≥4-fold increase in MIC) to the initial treatment (i.e., ceftolozane-tazobactam or ceftazidime-avibactam). Among 186 eligible patients, 102 (55%) received ceftolozane-tazobactam and 84 (45%) received ceftazidime-avibactam. In the post-IPW cohort, balance was achieved across all variables [e.g., demographics, severity of illness, severe immunocompromise, Charlson Comorbidity Index ≥5, continuous renal replacement therapy (CRRT), source of infection, combination therapy]. Thirty-day mortality was similar between the ceftolozane-tazobactam and ceftazidime-avibactam groups [21% vs 17%; adjusted odds ratio (aOR): 1.01 (95% confidence interval, CI: 0.90–1.14)]. Emergence of resistance was higher in the ceftolozane-tazobactam group [38% vs 25%; aOR: 1.89 (95% CI: 0.98–4.88)], but did not achieve statistical significance. Prolonged treatment durations and use of CRRT were associated with increased emergence of resistance (both P = 0.04). Although the survival of patients with DTR P. aeruginosa infections appears similar regardless of whether ceftolozane-tazobactam or ceftazidime-avibactam is prescribed, the emergence of resistance may be more concerning with the former. Plausible mechanistic explanations support these findings. Modifiable risk factors were identified that may mitigate this risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeCephalosporinsDrug CombinationsAzabicyclo CompoundsPseudomonas aeruginosaPseudomonas InfectionsTazobactamAnti-Bacterial AgentsMicrobial Sensitivity TestsHumansMaleFemaleProspective StudiesMiddle AgedAgedDrug Resistance, Multiple, BacterialTreatment Outcome

Stichwörter der Autor:innen

PDCPseudomonas aeruginosaantimicrobial resistanceceftolozane-tazobactam, ceftazidime-avibactam

Substanzen

Ceftazidimeavibactam, ceftazidime drug combinationCephalosporinsDrug CombinationsAzabicyclo Compoundsceftolozane, tazobactam drug combinationTazobactamAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Departments of Medicine, Pharmacology, Molecular Biology, and Microbiology, Medical Service and Center for Antimicrobial Resistance and Epidemiology, Louis Stokes Cleveland Veterans Affairs Medical Center, University Ho…
  • Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, USA.
  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Departments of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Robert A Bonomo, Sara M Karaba, Patricia J Simner, Pranita D Tamma

Förderung

  • HHS | National Institutes of Health (NIH)
  • NIAID NIH HHS

Zitieren

APA

Hareza, D. A., Cosgrove, S. E., Bonomo, R. A., Dzintars, K., Karaba, S. M., Hawes, A. M., Tekle, T., Simner, P. J., & Tamma, P. D. (2024). Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam. Antimicrobial Agents and Chemotherapy, 68(10). https://doi.org/10.1128/aac.00907-24

Vancouver

Hareza DA, Cosgrove SE, Bonomo RA, Dzintars K, Karaba SM, Hawes AM, et al. Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam. Antimicrobial Agents and Chemotherapy. 2024;68(10). doi:10.1128/aac.00907-24

BibTeX
@article{Hareza2024,
  author = {Hareza, Dariusz A and Cosgrove, Sara E and Bonomo, Robert A and Dzintars, Kathryn and Karaba, Sara M and Hawes, Armani M and Tekle, Tsigereda and Simner, Patricia J and Tamma, Pranita D},
  title = {Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {10},
  doi = {10.1128/aac.00907-24}
}
Kostenlos starten →